Effect of Pioglitazone on Bone Mineral Density in Patients with Nonalcoholic Steatohepatitis: A 36-Month Clinical Trial.

BackgroundThe effects of pioglitazone on bone metabolism are unclear. This study evaluated the long-term effects of pioglitazone on bone mineral density (BMD) and bone metabolism in patients with prediabetes or type 2 diabetes mellitus (T2DM) and non-alcoholic steatohepatitis (NASH). MethodsNinety-two patients with prediabetes or T2DM and biopsy-proven NASH with BMD and baseline biochemical bone measurements were included. Patients (mean [SEM] age 511years, 71% male, mean body mass index 34.50.5kg/m(2)) were randomly assigned to pioglitazone (45mg/day) or placebo for 18months, followed by an 18-month open-label pioglitazone treatment phase. Baseline, 18- and 36-month evaluations included plasma vitamin D and bone turnover biomarker levels, and BMD measurements at the spine, femoral neck, total hip, and one-third radius. ResultsAfter 18months of pioglitazone treatment, there were no differences in BMD versus placebo at either the femoral neck (P=0.87), total hip (P=0.78), or one-third radius (P=0.44); however, bone density decreased at the level of the spine with pioglitazone (-3.5%; P=0.002). During the extension phase (18-36months), patients had no further decreases in BMD or plasma biomarkers of bone turnover during pioglitazone treatment. No patient experienced a low-energy bone fracture. ConclusionsTreatment of patients with prediabetes or T2DM with pioglitazone for up to 3years was associated with decreased BMD at the level of the lumbar spine. This reduction in BMD at the lumbar spine at 18months versus placebo suggests an early deleterious effect of pioglitazone on bone metabolism.